
Opinion|Videos|October 10, 2024
Key Highlights on POD1UM-303 Presented at ESMO 2024
Panelists discuss how updates from the POD1UM-303/InterAACT2 trial presented at European Society for Medical Oncology Congress (ESMO) 2024 shed light on retifanlimab’s potential role in advancing treatment options for anal cancer patients.





































